Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS)

PHASE3CompletedINTERVENTIONAL
Enrollment

795

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

August 31, 2006

Study Completion Date

September 30, 2007

Conditions
Preterm BirthPregnancyMultifetal
Interventions
DRUG

17 alpha-hydroxyprogesterone caproate (17P)

Study coded medication is 250 mg of 17P as a 1 ml intramuscular injection (or 1 ml of placebo inert oil). Patients are seen weekly to administer the study drug through 34 weeks 6 days gestation or delivery, whichever occurs first.

Trial Locations (14)

10032

Columbia University, New York

15213

University of Pittsburgh Magee Womens Hospital, Pittsburgh

19107

Dexel University, Philadelphia

27157

Wake Forest University School of Medicine, Winston-Salem

27599

University of North Carolina - Chapel Hill, Chapel Hill

35233

University of Alabama - Birmingham, Birmingham

43210

Ohio State University, Columbus

44109

Case Western University, Cleveland

48201

Wayne State University, Detroit

60611

Northwestern University, Chicago

75235

University of Texas - Southwest, Dallas

77030

University of Texas - Houston, Houston

84132

University of Utah Medical Center, Salt Lake City

02905

Brown University, Providence

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

The George Washington University Biostatistics Center

OTHER

NCT00099164 - Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS) | Biotech Hunter | Biotech Hunter